Rein Therapeutics, Inc.: stockholders equity
Stockholders equity for Rein Therapeutics, Inc. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All Rein Therapeutics, Inc. financial histories
What this measure means
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
Exact concept: us-gaap:StockholdersEquity. Each value is a balance at the reporting date, not a flow earned over a year. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2014-12-31 to 2025-12-31. The SEC response was captured on 2026-09-20.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| At date | 2025-12-31 | 16,918,000 | USD | 2026-03-26 | 10-K · 0001193125-26-126385 |
| At date | 2024-12-31 | 54,392,000 | USD | 2026-03-26 | 10-K · 0001193125-26-126385 |
| At date | 2023-12-31 | 98,297,000 | USD | 2026-03-26 | 10-K · 0001193125-26-126385 |
| At date | 2022-12-31 | 18,623,000 | USD | 2025-04-07 | 10-K · 0000950170-25-051566 |
| At date | 2021-12-31 | 43,904,000 | USD | 2023-03-20 | 10-K · 0000950170-23-008767 |
| At date | 2020-12-31 | 12,162,000 | USD | 2023-03-20 | 10-K · 0000950170-23-008767 |
| At date | 2019-12-31 | 16,048,000 | USD | 2022-03-28 | 10-K · 0000950170-22-004774 |
| At date | 2018-12-31 | 19,600,000 | USD | 2021-03-24 | 10-K · 0001564590-21-015115 |
| At date | 2017-12-31 | 47,797,000 | USD | 2020-03-30 | 10-K · 0001564590-20-014155 |
| At date | 2016-12-31 | -111,806,000 | USD | 2019-03-29 | 10-K · 0001564590-19-010007 |
| At date | 2015-12-31 | -94,319,000 | USD | 2018-04-02 | 10-K · 0001564590-18-007403 |
| At date | 2014-12-31 | -82,044,000 | USD | 2018-04-02 | 10-K · 0001564590-18-007403 |
Related financial histories
- Rein Therapeutics, Inc.: total assets
- Rein Therapeutics, Inc.: total liabilities
- Rein Therapeutics, Inc.: cash and cash equivalents
- Rein Therapeutics, Inc.: net income or loss
- Rein Therapeutics, Inc.: operating cash flow
- Rein Therapeutics, Inc.: capital expenditure payments
- Rein Therapeutics, Inc.: revenue
- Rein Therapeutics, Inc.: contract revenue excluding tax
- Rein Therapeutics, Inc.: financing cash flow
- Rein Therapeutics, Inc.: investing cash flow
- Rein Therapeutics, Inc.: retained earnings or deficit
- Rein Therapeutics, Inc.: basic weighted-average shares
- Rein Therapeutics, Inc.: diluted weighted-average shares
- Rein Therapeutics, Inc.: basic earnings per share
- Rein Therapeutics, Inc.: diluted earnings per share
- Rein Therapeutics, Inc.: income tax expense or benefit
- Rein Therapeutics, Inc.: net property, plant and equipment
- Rein Therapeutics, Inc.: share-based compensation expense
- Rein Therapeutics, Inc.: operating income or loss
- Rein Therapeutics, Inc.: current assets
- Rein Therapeutics, Inc.: current liabilities
- Rein Therapeutics, Inc.: current accounts payable
- Rein Therapeutics, Inc.: operating expenses
- Rein Therapeutics, Inc.: research and development expense
Inspect the source
- Entity
- Rein Therapeutics, Inc. / CIK 0001420565
- Captured
- 2026-09-20T08:03:08.332Z
- SEC response SHA-256
738607e4a3c0c19670e61ee352369b40b71b7a47ee3fa97917f4b27e7539aaaf
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001420565.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))